Open AccessEscalation and de-escalation in HER2 positive early breast cancer
Author(s) -
Maria Vittoria Dieci,
Grazia Maria Vernaci,
Valentina Guarneri
Publication year - 2019
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/cco.0000000000000492
Subject(s) - medicine , trastuzumab , oncology , breast cancer , pertuzumab , anthracycline , regimen , adjuvant , chemotherapy , cancer
Current standard for HER2+ early breast cancer patients includes chemotherapy and trastuzumab for 1 year. The purpose of this article is to review available evidence on escalated treatment strategies for high-risk patients and de-escalated treatments for patients at low risk of relapse or high risk of cardiac toxicity.